UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1958) 1958
science & technology (1576) 1576
anilides - therapeutic use (1516) 1516
life sciences & biomedicine (1490) 1490
male (1443) 1443
anilides - pharmacology (701) 701
middle aged (689) 689
animals (677) 677
aged (653) 653
female (571) 571
prostatic neoplasms - drug therapy (526) 526
oncology (446) 446
pyridines - therapeutic use (444) 444
antineoplastic agents - therapeutic use (439) 439
anilides - administration & dosage (390) 390
androgen antagonists - therapeutic use (389) 389
anilides - adverse effects (386) 386
prostate cancer (340) 340
adult (332) 332
abridged index medicus (325) 325
pharmacology & pharmacy (308) 308
mice (304) 304
tosyl compounds (303) 303
nitriles (300) 300
treatment outcome (295) 295
aged, 80 and over (255) 255
care and treatment (239) 239
cancer (237) 237
prostatic neoplasms - pathology (236) 236
urology & nephrology (226) 226
cell line, tumor (215) 215
nitriles - therapeutic use (214) 214
tosyl compounds - therapeutic use (205) 205
encainide (203) 203
carcinoma, basal cell - drug therapy (176) 176
pyridines - pharmacology (175) 175
rats (174) 174
skin neoplasms - drug therapy (172) 172
drug therapy, combination (169) 169
anti-arrhythmia agents - therapeutic use (166) 166
signal transduction - drug effects (165) 165
antineoplastic agents, hormonal - therapeutic use (158) 158
flutamide - therapeutic use (158) 158
time factors (154) 154
health aspects (147) 147
clinical trials as topic (145) 145
antineoplastic agents - pharmacology (144) 144
dose-response relationship, drug (142) 142
prostate-specific antigen - blood (142) 142
bicalutamide (141) 141
research (139) 139
antineoplastic combined chemotherapy protocols - therapeutic use (137) 137
analysis (136) 136
drug therapy (133) 133
metastasis (129) 129
antineoplastic agents - adverse effects (123) 123
arrhythmias, cardiac - drug therapy (123) 123
pyridines - adverse effects (123) 123
hedgehog proteins - antagonists & inhibitors (122) 122
antiviral agents - therapeutic use (118) 118
prostatic neoplasms - blood (118) 118
dermatology (116) 116
anilides - pharmacokinetics (110) 110
carbamates - therapeutic use (110) 110
uracil - analogs & derivatives (108) 108
hepatitis c, chronic - drug therapy (107) 107
follow-up studies (106) 106
patients (106) 106
skin neoplasms - pathology (106) 106
macrocyclic compounds - therapeutic use (104) 104
medicine & public health (103) 103
tumors (103) 103
adenocarcinoma - drug therapy (102) 102
disease models, animal (102) 102
basal cell carcinoma (100) 100
combined modality therapy (100) 100
vismodegib (100) 100
mutation (99) 99
neoplasm staging (99) 99
cell proliferation - drug effects (98) 98
clinical trials (98) 98
disease progression (98) 98
ppar gamma - metabolism (98) 98
ppar gamma - antagonists & inhibitors (97) 97
prostatic neoplasms - metabolism (97) 97
sulfonamides - therapeutic use (97) 97
administration, oral (95) 95
anilides - chemistry (95) 95
research article (95) 95
cell biology (94) 94
nitriles - administration & dosage (94) 94
receptors, androgen - metabolism (94) 94
androgens (93) 93
hepacivirus - genetics (93) 93
protein kinase inhibitors - therapeutic use (93) 93
tosyl compounds - administration & dosage (93) 93
prostatic neoplasms - surgery (92) 92
androgen antagonists - administration & dosage (91) 91
carcinoma, basal cell - pathology (91) 91
prostatic neoplasms - therapy (90) 90
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2213) 2213
German (51) 51
Japanese (32) 32
French (21) 21
Italian (14) 14
Spanish (14) 14
Chinese (11) 11
Russian (9) 9
Czech (7) 7
Polish (6) 6
Portuguese (5) 5
Norwegian (4) 4
Dutch (3) 3
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 03/2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Index Medicus | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 2017, Volume 24, Issue 16, pp. 1 - 16
... the most clinically practiced therapeutic approaches, the modulation of multiple proteins by a single drug, in accordance... 
Tumor microenvironment | Fda-Approved drugs | Multitargeted drugs | Anticancer agents | Polypharmacology | Tyrosine kinase receptors | Oncogene addiction | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Pyrazoles - therapeutic use | Pyridines - chemistry | Humans | Anilides - chemistry | Imidazoles - chemistry | Imatinib Mesylate - therapeutic use | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Niacinamide - chemistry | Phenylurea Compounds - chemistry | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Imidazoles - therapeutic use | Pyrroles - therapeutic use | Quinazolines - chemistry | Pyridazines - therapeutic use | Pyridines - therapeutic use | Piperidines - chemistry | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Receptor Protein-Tyrosine Kinases - metabolism | Imatinib Mesylate - chemistry | Neoplasms - drug therapy | Pyridazines - chemistry | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Pyrroles - chemistry | Indoles - therapeutic use | Neoplasms - pathology | Indoles - chemistry | Tyrosine | Cell proliferation | Drugs | Medical research | Phenotypes | Clinical trials | Kinases | Proteins | Inhibitors | Modulation | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Cancer
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 11/2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer | Index Medicus
Journal Article
CA: a cancer journal for clinicians, ISSN 0007-9235, 09/2012, Volume 62, Issue 5, pp. 299 - 308
There have been more drugs approved by the US Food and Drug Administration for the treatment of castration-resistant prostate cancer in the past 3 years than... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Castration - adverse effects | Prostate-Specific Antigen | Anilides - therapeutic use | Taxoids - pharmacology | Phenylthiohydantoin - therapeutic use | Cancer Vaccines - pharmacology | Humans | Tissue Extracts - pharmacology | Male | Antineoplastic Agents - therapeutic use | Androstenols - therapeutic use | Prostatic Neoplasms - therapy | Taxoids - therapeutic use | Cancer Vaccines - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Radiopharmaceuticals - pharmacology | Pyridines - therapeutic use | Phenylthiohydantoin - pharmacology | Antibodies, Monoclonal, Humanized - therapeutic use | Radium - pharmacology | Androstenols - pharmacology | Androstenes | Clinical Trials as Topic | Tissue Extracts - therapeutic use | Denosumab | Radium - therapeutic use | Phenylthiohydantoin - analogs & derivatives | RANK Ligand - antagonists & inhibitors | Anilides - pharmacology | Pyridines - pharmacology | Radiopharmaceuticals - therapeutic use | Care and treatment | Drug therapy | Drug resistance | Laws, regulations and rules | Prostate cancer | Drug approval | Clinical trials | Chemotherapy | Castration | Pathogenesis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article